Effect of ticagrelor on endothelial calcium signalling and barrier functionFinancial support: The study was supported by an unrestricted grant from AstraZeneca to M. Aslam.
Received:06 April 2016
Accepted after major revision:05 November 2016
13 November 2017 (online)
The P2Y12 receptor is a Gi-coupled receptor whose activation inhibits adenylyl cyclase and thereby reduces the concentration of intracellular cAMP. Here the hypothesis was tested whether AR-C 66096 or ticagrelor, two direct-acting and reversibly binding P2Y12 receptor antagonists, protect endothelial cell (EC) barrier function by raising intracellular cAMP in ECs. The study was carried out on primary human umbilical vein ECs (HUVECs) and human pulmonary microvascular ECs (hPMECs). AR-C66096 (10 µM) induced a 50 % increase in cAMP in ECs whereas ticagrelor (2–10 µM) had no effect. Likewise, AR-C666096 antagonised thrombin-induced hyperpermeability in both HUVECs and hPMECs, but ticagrelor had no effect on basal EC monolayer permeability. Ticagrelor, however, sensitised ECs for thrombin-induced hyperpermeability and potentiated the thrombin effect. Ticagrelor but not AR-C66096 caused an increase in cytosolic calcium ([Ca2+]i). This increase in [Ca2+]i was abrogated by LaCl3 (Ca2+ influx inhibitor) but not by xestospongin C (IP3 receptor antagonist) or by depletion of intracellular stores with thapsigargin, suggesting a Ca2+ influx from the extracellular space. Accordingly, ticagrelor caused an increase in myosin light chain (MLC) phosphorylation, an important regulator of EC contractile machinery and thus permeability, which was abrogated by LaCl3. The ability of ticagrelor to potentiate EC permeability was abrogated by a MLC kinase inhibitor (ML-7; 10 µM). Our data demonstrate that the P2Y12 receptor antagonist AR-C66096 exerts a protective effect on ECs in vitro, possibly by raising intracellular cAMP, whereas ticagrelor sensitises EC barrier function by inducing Ca2+ influx and activating downstream EC contractile machinery.
Supplementary Material to this article is available online at www.thrombosis-online.com.
- 1 Gawlowski DM, Duran WN. Dose-related effects of adenosine and bradykinin on microvascular permselectivity to macromolecules in the hamster cheek pouch. Circ Res 1986; 58: 348-355.
- 2 Adamson RH, Liu B, Fry GN. et al. Microvascular permeability and number of tight junctions are modulated by cAMP.. Am J Physiol 1998; 274: H1885-H1894..
- 3 Farmer PJ, Bernier SG, Lepage A. et al. Permeability of endothelial monolayers to albumin is increased by bradykinin and inhibited by prostaglandins.. Am J Physiol Lung Cell Mol Physiol 2001; 280: L732-L738.
- 4 Chen L, Kis B, Hashimoto H. et al. Adrenomedullin 2 protects rat cerebral endothelial cells from oxidative damage in vitro.. Brain Res 2006; 1086: 42-49.
- 5 Langeler EG, Fiers W, van Hinsbergh VW. Effects of tumor necrosis factor on prostacyclin production and the barrier function of human endothelial cell monolayers. Arterioscler Thromb 1991; 11: 872-881.
- 6 Comerford KM, Lawrence DW, Synnestvedt K. et al. Role of vasodilator-stimulated phosphoprotein in PKA-induced changes in endothelial junctional permeability.. FASEB J 2002; 16: 583-585.
- 7 Qiao J, Huang F, Lum H. PKA inhibits RhoA activation: a protection mechanism against endothelial barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 2003; 284: L972-L980.
- 8 He P, Curry FE. Differential actions of cAMP on endothelial [Ca2+]i and permeability in microvessels exposed to ATP. Am J Physiol 1993; 265: H1019-H1023.
- 9 He P, Zeng M, Curry FE. Dominant role of cAMP in regulation of microvessel permeability. Am J Physiol Heart Circ Physiol 2000; 278: H1124-H1133.
- 10 Hippenstiel S, Witzenrath M, Schmeck B. et al. Adrenomedullin reduces endothelial hyperpermeability.. Circ Res 2002; 91: 618-625.
- 11 Yuan SY. Protein kinase signaling in the modulation of microvascular permeability. Vascul Pharmacol 2002; 39: 213-223.
- 12 Adamson RH, Zeng M, Adamson GN. et al. PAF- and bradykinin-induced hyperpermeability of rat venules is independent of actin-myosin contraction.. Am J Physiol Heart Circ Physiol 2003; 285: H406-H417.
- 13 Storey RF, Angiolillo DJ, Patil SB. et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.. J Am Coll Cardiol 2010; 56: 1456-1462.
- 14 Shanker G, Kontos JL, Eckman DM. et al. Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts.. J Thromb Thrombolysis 2006; 22: 213-220.
- 15 Uehara K, Uehara A. P2Y1, P2Y6, and P2Y12 receptors in rat splenic sinus endothelial cells: an immunohistochemical and ultrastructural study. Histochem Cell Biol 2011; 136: 557-567.
- 16 Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004; 113: 340-345.
- 17 Yuan Y, Huang Q, Wu HM. Myosin light chain phosphorylation: modulation of basal and agonist-stimulated venular permeability. Am J Physiol 1997; 272: H1437-H1443.
- 18 Aslam M, Pfeil U, Gündüz D. et al. Intermedin/adrenomedullin2 stabilises endothelial barrier and antagonises thrombin-induced barrier failure.. Br J Pharmacol 2012; 165: 208-222.
- 19 Aslam M, Schlüter KD, Rohrbach S. et al. Hypoxia/reoxygenation-induced endothelial barrier failure: Role of RhoA, Rac1, and MLCK.. J Physiol 2013; 591: 461-473.
- 20 Aslam M, Härtel FV, Arshad M. et al. cAMP/PKA antagonizes thrombin-induced inactivation of endothelial myosin light chain phosphatase: Role of CPI-17.. Cardiovasc Res 2010; 87: 375-384.
- 21 Aungraheeta R, Conibear A, Butler M. et al. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelorBlood. 2016 Epub ahead of print.
- 22 Teng R, Oliver S, Hayes MA. et al. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects.. Drug Metab Dispos 2010; 38: 1514-1521.
- 23 Aslam M, Tanislav C, Troidl C. et al. cAMP controls the restoration of endothelial barrier function after thrombin-induced hyperpermeability via Rac1 activation.. Physiol Rep 2014; 02: e12175-e12187.
- 24 Pfeil U, Aslam M, Paddenberg R. et al. Intermedin/adrenomedullin-2 is a hypoxia-induced endothelial peptide that stabilizes pulmonary microvascular permeability.. Am J Physiol Lung Cell Mol Physiol 2009; 297: L837-L845.
- 25 Kitazawa T, Eto M, Woodsome TP. et al. Phosphorylation of the myosin phosphatase targeting subunit and CPI-17 during Ca2+ sensitization in rabbit smooth muscle.. J Physiol 2003; 546: 879-889.
- 26 Birukova AA, Smurova K, Birukov KG. et al. Role of Rho GTPases in thrombin-induced lung vascular endothelial cells barrier dysfunction.. Microvasc Res 2004; 67: 64-77.
- 27 Armstrong D, Summers C, Ewart L. et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1.. J Cardiovasc Pharmacol Ther 2014; 19: 209-219.
- 28 Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol 2014; 63: 2503-2509.
- 29 Nylander S, Femia EA, Scavone M. et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism.. J Thromb Haemost 2013; 11: 1867-1876.
- 30 Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G. et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans.. J Am Coll Cardiol 2013; 61: 723-727.
- 31 Sasaki Y, Hoshi M, Akazawa C. et al. Selective expression of Gi/o-coupled ATP receptor P2Y12 in microglia in rat brain.. Glia 2003; 44: 242-250.
- 32 Wihlborg AK, Wang L, Braun OO. et al. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels.. Arterioscler Thromb Vasc Biol 2004; 24: 1810-1815.
- 33 Savi P, Zachayus JL, Delesque-Touchard N. et al. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts.. Proc Natl Acad Sci USA 2006; 103: 11069-11074.
- 34 Ding Z, Bynagari YS, Mada SR. et al. Studies on the role of the extracellular cysteines and oligomeric structures of the P2Y12 receptor when interacting with antagonists.. J Thromb Haemost 2009; 07: 232-234.
- 35 Tiruppathi C, Minshall RD, Paria BC. et al. Role of Ca2+ signaling in the regulation of endothelial permeability.. Vascul Pharmacol 2002; 39: 173-185.
- 36 Sandoval R, Malik AB, Naqvi T. et al. Requirement for Ca2+ signaling in the mechanism of thrombin-induced increase in endothelial permeability.. Am J Physiol Lung Cell Mol Physiol 2001; 280: L239-L247.
- 37 Cheng KT, Rosenhouse-Dantsker A, Malik AB. Contribution and Regulation of Calcium Channels in Endothelial Cells. In: Vascular Ion Channels in Physiology and Disease. Springer International Publishing 2016; pp.37-62.
- 38 Werthmann RC, von HK, Nikolaev VO. et al. Real time monitoring of cAMP levels in living endothelial cells: thrombin transiently inhibits adenylyl cyclase 6.. J Physiol 2009; 587: 4091-4104.
- 39 Halls ML, Cooper DM. Regulation by Ca2+-signaling pathways of adenylyl cyclases. Cold Spring Harb Perspect Biol 2011; 03: a004143.
- 40 Ohman J, Kudira R, Albinsson S. et al. Ticagrelor induces adenosine triphosphate release from human red blood cells.. Biochem Biophys Res Commun 2012; 418: 754-758.
- 41 Cinar E, Zhou S, DeCourcey J. et al. Piezo1 regulates mechanotransductive release of ATP from human RBCs.. Proc Natl Acad Sci USA 2015; 112: 11783-11788.
- 42 Gündüz D, Kasseckert SA, Härtel FV. et al. Accumulation of extracellular ATP protects against acute reperfusion injury in rat heart endothelial cells.. Cardiovasc Res 2006; 71: 764-773.
- 43 Gündüz D, Aslam M, Krieger U. et al. Opposing effects of ATP and adenosine on barrier function of rat coronary microvasculature.. J Mol Cell Cardiol 2012; 52: 962-970.